Trials / Completed
CompletedNCT01926860
PCV13 + Hepatitis A Vaccine for Adults
Immune Response to Pneumococcal Conjugate Vaccine in Adults Receiving Hepatitis A Vaccine at the Same Time
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 305 (actual)
- Sponsor
- Helsinki University Central Hospital · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Accepted
Summary
The present study explores whether a simultaneously given hepatitis A vaccine (Epaxal) will have an impact on the immune response to PCV13 (pneumococcal conjugate vaccine; Prevenar13) vaccine in adults. The immune response to PCV13 is measured as levels of serotype specific serum antibodies and their opsonophagocytic activity. The results of volunteers receiving PCV13 and Epaxal will be compared to that in a control groups of adults receiving either hepatitis A or PCV13 vaccines only.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Prevenar13 | |
| BIOLOGICAL | Hepatitis A vaccine |
Timeline
- Start date
- 2013-08-24
- Primary completion
- 2019-10-28
- Completion
- 2020-04-28
- First posted
- 2013-08-21
- Last updated
- 2024-12-05
Locations
2 sites across 2 countries: Finland, Sweden
Source: ClinicalTrials.gov record NCT01926860. Inclusion in this directory is not an endorsement.